Altogether, our results suggest that high valent treatments, achieved either through a combination of clinical Abs or meditope technology, have the capacity to arrange HER2 on the membrane of breast cancer cells, may abrogate elements of the HER2 signaling cascade, and may ultimately lead to the elimination of breast cancer cells. Here, ERBB2 is linked to breast carcinoma.